Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection

Hua Ye1,2,3 · Yuan Yuan1,2,3 · Ping Chen1,2,3 · Qi Zheng1,2,3

Received: 22 July 2021 / Accepted: 7 March 2022 / Published online: 3 May 2022
© The Author(s) 2022

Abstract

Background Gastrectomy with lymphadenectomy is recommended for early gastric Neuroendocrine carcinoma (G-NEC). We attempted to determine the prevalence and risk factors of metastasis of T1 G-NEC and compare the long-term survival of patients after receiving endoscopic therapy (ET) and radical surgery.

Methods In this study, 205 patients in total with T1 G-NEC were collected from the Surveillance Epidemiology and End Result database. Independent predictors of metastasis were identified by Logistic regression analysis, followed by the calculation of both cancer-specific survival (CSS) and overall survival (OS).

Results Twenty-five patients (12.2%) were burdened with metastasis at initial diagnosis, with a prevalence of 5.2% (3/58) in mucosa lesions and 16.2% (16/99) in submucosa lesions ($P=0.045$). No metastasis was detected in lesions with mucosa involvement and tumors $\leq 20$ mm (0%, 0/49). The most significant risk factor for metastasis was tumors $>20$ mm [odds ratio (OR) 18.64; 95% confidence interval (CI) 4.01–86.68; $P<0.001$]. For patients with T1N0M0 G-NEC who received ET or surgery, the 10-year OS was similar between the mucosa extension and submucosa extension groups, which was 91.56% in ET group vs 87.50% in surgery group ($P=0.62$) and 57.33% vs 77.83% ($P=0.11$), respectively. In addition, the 10-year CSS was also similar between the mucosa extension and submucosa extension groups with 97.30% in ET vs 100% in surgery ($P=0.51$) and 97.62% vs 86.49% ($P=0.65$).

Conclusions In G-NEC, tumors $>20$ mm were considered as the most significant risk factor for metastasis. ET seemed adequate for the lesions with mucosa involvement and size $\leq 2$ cm.

Keywords Endoscopic treatment · Surgery · Metastasis · Survival · Gastric neuroendocrine carcinoma

Neuroendocrine neoplasms (NENs) are defined as a group of epithelial neoplasms with predominant neuroendocrine differentiation based on the 2019 World Health Organization (WHO) classification, which can be categorized into two main groups of well-differentiated NETs and poorly differentiated neuroendocrine carcinomas (NECs) [1]. G-NENs account for only 4% of all NENs, with an incidence of 0.3 per 100,000 annually [2]. However, the incidence of G-NENs has remarkably increased over the past decades, due to various of factors, including accumulative diagnosing experience both clinically and pathologically, enhanced physician awareness and endoscopic surveillance [3]. At present, surgical resection (SR) is widely considered as the backbone of potentially curative approach for G-NENs. Therefore, different surgical approaches have been prevalently applied for G-NENs, from traditional open surgery to endoscopic and laparoscopic resection [4]. Especially, endoscopic therapy (ET), instead of surgery, has been increasingly performed to treat G-NETs of early stage. ET for gastric neuroendocrine tumor (G-NETs) is possible when the tumor is less than 20 mm in size with the infiltration no more than muscularis propria [5]. The outcomes of gastric NENs (G-NENs) vary

---

Hua Ye and Yuan Yuan have contributed equally to this work.

Qi Zheng
oktellu@hotmail.com

1 Department of Gastrointestinal and Hernia Ward, HwaMei Hospital, University of Chinese Academy of Sciences, No. 41 Xibei Street, Ningbo, Zhejiang, China
2 Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China
3 Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, China
significantly between gastric neuroendocrine carcinomas (G-NEC) and G-NETS. In addition, to our knowledge, studies comparing the therapeutic outcomes between ET and SR in early stage of G-NEC are rare.

Based on Surveillance Epidemiology and End Result (SEER) database, we attempted to determine the prevalence of metastasis in early stage of G-NEC and further reveal risk factors for metastasis. Finally, we also compared the long-term survival between ET and SR.

**Materials and methods**

**Study cohort**

The SEER database supported by National Cancer Institute (NCI) covers approximately 28% of the US population from different geographic regions (18 cancer registries) from 2004 to 2015. The SEER database is well-known for its collection and recording on comprehensive information concerning tumor incidence and patient survival. After acquiring access to SEER database and gaining institutional approval, we extracted necessary demographic data, tumor characteristics, therapeutic approach and patient survival by utilizing data items and codes based on NAACCR (the last follow-up was December 31, 2018) [6]. Access to SEER database was obtained, and our study gained institutional approval. This study was approved by the institutional ethical review board of HwaMei Hospital, University of Chinese Academy of Sciences, and IRB approval was also obtained.

**Inclusion and exclusion criteria**

Eligible patients were included if they: (1) were diagnosed between 2004 and 2015; (2) were 18 years or older; (3) had Neuroendocrine carcinoma (ENC)(8246/3); (4) had active follow-up data; (5) G-NEC was the first or only primary malignancy; (6) had T1 G-NEC (site codes, C16.0-C16.9) and were treated with either ET or SR based on the SEER database. Specifically, ET referred to endoscopic treatment for local tumor excision with pathology specimen. According to the 8th edition of AJCC TNM staging, G-NEC was referred to TNM staging of gastric carcinoma [7]. Tumor with infiltration into lamina propria or submucosa was defined as T1. The exclusion criteria were as follows: (1) patients with survival <1 month, mostly likely due to perioperative complications; (2) their pathological samples were unavailable.

**Statistical analysis**

The following data were extracted from SEER database, including age at diagnosis, race, gender, year of diagnosis, tumor grade, tumor size, histology, metastasis, survival (months) and death cause. Overall survival (OS) as well as cancer-specific survival (CSS) were used as the endpoints. Fisher’s exact test or Pearson’s test was employed to compare categorical parameters. Additionally, multivariate logistic regression analysis was used to identity risk factors for metastasis of patients with T1 G-NEC, which was displayed as odd ratios (ORs) and 95% confidence intervals (CIs). In addition, multivariate Cox regression analysis was performed to calculate the adjusted hazard ratios (HRs) and 95% CIs. For comparative long-term survival analysis between ET and SR, patients with T1N0M0 G-NEC were collected, who had low metastasis risks and also received either ET or SR. Eligible patients were subsequently categorized into two groups, namely ET and SR. Specifically, we only extracted the most-invasive tumor-directed treatment from the SEER database.

Statistical analysis was performed using SPSS version 23.0 (SPSS Inc., Chicago, IL, USA). Survival curves were plotted by GraphPad Prism 6.0 (GraphPad Software, San Diego, CA). A two-sided $P<0.05$ was suggestive of statistical significance.

**Results**

**Patient features**

A total of 205 patients with T1 (confined to mucosa or submucosa) G-NEC were identified (with mean age of 59 ± 14 years; 125 female [61.0%]; 161 white [78.5%]). In addition, 127 (62%), 40 (19.5%) and 38 (18.5%) patients had tumors $\leq$ 10 mm, 10 to 20 mm and > 20 mm in diameters, respectively. One hundred and seventy-two (95.6%) G-NEC showed well or moderate differentiation out of 180 cases with accessible information on tumor grade. Table 1 summarized the specific information on patient demographics and tumor features.

**Frequency and risk factors for metastasis**

Twenty-five patients (12.2%) suffered metastasis at initial diagnosis, with the incidence of 5.2% (3/58) in mucosa lesions and 16.2% (16/99) in submucosa lesions ($P=0.045$). With the increase of tumor size, the possibility of metastasis was
also elevated. To be specific, the metastasis rates were 2.3% (3/127), 17.5% (7/40), and 39.5% (15/38) in tumors with \( \leq 10 \) mm, 10 to 20 mm and > 20 mm diameters, respectively. Metastasis was not detected for lesions with mucosa involvement and tumors in size \( \leq 20 \) mm (0%, 0/49), which rose to 33.3% (3/9) for tumors > 20 mm. Metastasis rate was 5.7% (3/53), 20.7% (6/27) and 41.2% (7/17) for lesions with submucosa involvement and tumor with \( \leq 10 \) mm, 10 to 20 mm and > 20 mm diameters, respectively.

Multivariate logistic regression model showed that the most significant risk factor of metastasis was tumors > 20 mm (OR 18.64; 95% CI 4.01–86.68; \( P < 0.001 \)). The 2010–2015 years of diagnosis (OR 0.167; 95% CI 0.049–0.574; \( P = 0.004 \), compared to 2004–2009 years of diagnosis), male (OR 3.534; 95% CI 1.046–11.945; \( P = 0.042 \), compared to female) were also significant risk factors of metastasis (Table 2).

Survival analysis based on invasion depth and therapeutic approaches

For long-term survival analysis, 180 T1N0M0 G-NEC patients at low risks of metastasis receiving either ET or SR were enrolled, including 116 patients (64.4%) undergoing ET and 64 patients (35.6%) receiving SR. Table 3

| Table 1 Association of clinical and pathologic variables of patients with T1 gastric neuroendocrine carcinoma with survival |
|---------------------|------------------|-----------|----------|----------|
| Characteristic      | \( n (\%), \text{total} \) | \text{Mean (month) 95\% CI} | Statistic | \( P \)   |
| Age (years)         |                          |                        |           |          |
| Up to 59            | 92                     | 157 (145.35–168.05)   | 6.723     | 0.01     |
| 60+                 | 113                    | 119 (106.58–130.45)   |           |          |
| Gender              |                          |                        |           |          |
| Female              | 125                    | 149 (138.05–160.41)   | 3.361     | 0.067    |
| Male                | 80                     | 117 (103.46–130.44)   |           |          |
| Race                |                          |                        |           |          |
| White               | 161                    | 142 (131.55–152.80)   | 0.272     | 0.873    |
| Black               | 34                     | 129 (111.09–146.93)   |           |          |
| Others\(^{a}\)      | 10                     | 108 (74.12–143.65)    |           |          |
| Year of diagnosis   |                          |                        |           |          |
| 2004–2009           | 57                     | 131 (113.35–148.29)   | 3.0       | 0.083    |
| 2010–2015           | 148                    | 93 (87.92–98.04)      |           |          |
| Tumor size (cm)     |                          |                        |           |          |
| < 1                 | 127                    | 144 (131.92–155.97)   | 2.043     | 0.36     |
| 1–2                 | 40                     | 133 (117.15–149.78)   |           |          |
| 2+                  | 38                     | 131 (108.83–154.01)   |           |          |
| Invasion depth      |                          |                        |           |          |
| Mucosal involvement | 58                     | 158 (145.65–170.56)   | 3.83      | 0.147    |
| Submucosal involvement | 99                  | 138 (123.22–152.46)  |           |          |
| Mucosal or submucosal, not otherwise specified | 48 | 113 (96.80–129.74) | | |
| Grade               |                          |                        |           |          |
| Well-differentiated | 147                    | 151 (141.35–160.88)   | 9.092     | 0.028    |
| Moderately differentiated | 25              | 88 (70.99–105.05)     |           |          |
| Poorly/undifferentiated | 8                   | 68 (37.96–97.79)      |           |          |
| Unknown             | 25                     | 96 (75.04–117.20)     |           |          |
| Metastasis          |                          |                        |           |          |
| No metastasis       | 180                    | 146 (136.45–155.77)   | 6.99      | 0.008    |
| Metastasis          | 25                     | 113 (82.77–143.75)    |           |          |
| Treatment           |                          |                        |           |          |
| Endoscopic therapy  | 117                    | 143 (130.19–155.37)   | 0.035     | 0.852    |
| Surgery             | 88                     | 141 (127.12–155.50)   |           |          |

\(^{a}\)American Indian/Alaska Native, Asian/Pacific Islander
summarized patient features from two different groups. 31 of 180 patients died during follow-up (71.0 ± 67.0 months). As unadjusted analyses revealed, there was no OS difference between ET and SR groups in mucosa lesion and submucosa lesion subgroups. Figure 1A and C showed that for mucosa extension group, the 10-year OS was 91.56% and 87.50% in ET group and SR group, respectively (P = 0.62). For submucosa lesions, the 10-year OS was 57.33% and 77.83% in ET group and SR group, respectively (P = 0.11).

It could also be observed from Fig. 1B and D that in the mucosa extension group, 10-year CSS rate was not statistically different between ET group (97.30%) and SR group (100%) (P = 0.51). For submucosa lesions category, the 10-year CSS rate was also similar between ET group (97.62%) and SR group (86.49%) (P = 0.65).

Adjusted multivariate Cox regression analysis persistently demonstrated that age, year of diagnosis, and tumor grade were significant prognostic factors for both OS and CSS in patients with T1 G-NEC (Table 4).

**Discussion**

G-NEC, an uncommon disease, accounts for 0.1–0.6% of all types of gastric carcinoma. As a highly aggressive malignancy, G-NEC is characterized by rapid growth, high rate of metastasis and extremely poor prognosis, which is generally more malignant than gastric adenocarcinoma [8]. Due to the recent prevalence of endoscopy for the gastrointestinal tract, there have been an increasing number of asymptomatic early gastric NETs (G-NETs) in clinical practice globally [3]. It is consistent with our findings during all time periods (27.8% in 2004–2009, 72.2% in 2010–2015). It is observed that ET application for T1 lesion has been increasing over time, from 42.1 in 2004–2009, to 62.8% in 2010–2015. Due to the rapidly improved endoscopic techniques, including conventional endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), EMR with ligation device and cap-assisted EMR, higher en bloc and R0 resection rates with lower rates of relevant adverse events are possible, which renders ET as a possible selection for deeper and larger lesions. Moreover, with the accumulative acceptance of ET, the trend of ET is likely to increase [4, 9].

In the 2019 WHO classification, gastrointestinal NETs are classified by the grade of malignancy of each component into NET G1, G2, G3 and NEC [10]. Moreover, there are three types of gastric NETs: type I, NETs generally associated with autoimmune chronic atrophic gastritis; type II, NETs related to Zollinger–Ellison syndrome and multiple endocrine neoplasia type 1 (MEN 1); and type III, aggressive NETs with reportedly sporadic occurrence [11]. National Comprehensive Cancer Network (NCCN) guidelines recommend ET for type I and II gastric NET (≦2 cm) [12]. According to European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines and NCCN guidelines for type III gastric NET G3, NEC should be managed with radical surgery, while ET is not recommended even for early-stage lesion. However, ET is an alternative to traditional surgery, which is minimally invasive and increases post-therapeutic quality of life.

As far as we know, it is the first research to compare the long-term survival between ET and SR in T1 G-NEC based on SEER database. Consequently, lesions with mucosa involvement and tumors (≦20 mm, metastasis was
identified 0%. Multivariate logistic regression analysis revealed that the most significant risk factor of metastasis was tumors > 20 mm (OR 18.64; 95% CI 4.01–86.68; \( P < 0.001 \)). Other risk factors included year of diagnosis (2004–2009 vs 2010–2015) and male. Adjusted multivariate Cox regression analysis persistently revealed that age (≧ 60 years), year of diagnosis (2004–2009 vs 2010–2015) and tumor grade were significant prognostic factors for OS as well as CSS in T1 G-NEC patients. It was found that the proportion of mucosal lesions in year of diagnosis from 2010 to 2015 was higher than that in year of diagnosis from 2004 to 2009 (29.1% vs 26.3%). Therefore, it was likely to cause better prognosis in 2010–2015. Considering the possible recurrence of G-NETs in the long run, abdominal and pelvic multiphasic CT or MRI for at least 10 years after complete resection are recommended by NCCN guidelines [12]. In this study, the long-term (≧ 10 years) OS and CSS rates were similar between ET and SR in T1N0M0 G-NEC patients (Fig. 1A–D), implicating that ET was a promising approach for subjects with low risk of metastasis.

In some researches, ET was recommended for T1 type 3 G-NETs ≤ 10 mm, with G1 grade, with excellent survival despite the possible LNM risk, ET might be an alternative therapeutic option [9, 13]. Our study focused solely on T1 G-NEC, with a large population from the SEER database, and found that the frequency of metastasis of G-NEC mucosa extension and submucosa extension was 5.2% and

| Table 3 | Clinicopathologic characteristics of patients with T1N0M0 gastric Neuroendocrine carcinoma in the endoscopic therapy and surgery groups |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Characteristic   | Endoscopic therapy group (n = 116) | Surgery group (n = 64) | Statistic | \( P \) |
| Age (years)     | χ² = 0.082       | 0.875           |
| Up to 59        | 50              | 29              |
| 60+             | 66              | 35              |
| Gender          | χ² = 1.114       | 0.33            |
| Female          | 78              | 38              |
| Male            | 38              | 26              |
| Race            | χ² = 6.426       | 0.04            |
| White           | 101             | 46              |
| Black           | 12              | 15              |
| Othersa         | 3               | 3               |
| Year of diagnosis | χ² = 1.275    | 0.274           |
| 2004–2009       | 24              | 18              |
| 2010–2015       | 92              | 46              |
| Tumor size (cm) | χ² = 25.285     | < 0.001         |
| < 1             | 94              | 30              |
| 1–2             | 10              | 23              |
| 2+              | 12              | 11              |
| Invasion depth  | χ² = 5.996      | 0.051           |
| Mucosal involvement | 38         | 17              |
| Submucosal involvement | 46    | 37              |
| Mucosal or submucosal, not otherwise specified | 32 | 10 |
| Grade           | χ² = 12.545     | 0.004           |
| Well-differentiated | 93            | 42              |
| Moderately differentiated | 8  | 13              |
| Poorly/undifferentiated | 1 | 4 |
| Unknown         | 14              | 5               |

aAmerican Indian/Alaska Native, Asian/Pacific Islander
16.2%, respectively. Furthermore, the lesions with mucosa involvement and in tumor \( \leq 20 \) mm, metastasis was identified 0%. Toshiaki analyzed that LNM rate of 176 G-NETs confined to SM2 (tumor invasion of or over 0.5 mm into muscularis mucosae) was 14.1% [9]. Although NETs were not classified by tumor grade, their outcomes were similar to ours (LNM rate of 16.2% in submucosa lesions). In our research, metastasis was similarly related to tumor size, tumor invasion and tumor differentiation [14, 15]. NCCN and ENETS guidelines highly recommend EUS to assess tumor infiltration depth, regional lymph node involvement as well as tumor histology before resecting tumor [12, 16]. Thus, in patients with T1 G-NEC and tumor \( \leq 20 \) mm, we should perform EUS before selecting ET.

However, there are certain limitations of this study. To begin with, in this retrospective and observational study, residual confounding is unavoidable. Secondly, inaccessible information on certain variables was recorded by SEER (such as tumor grade, incidental diagnosis, Ki67, the presence of vascular invasion and mitotic rates). Information on other factors such as therapy-associated adverse events, resection margins, endoscopic and surgical procedure details (EMR or endoscopic submucosal dissection; open surgery or minimally invasive techniques), and disease recurrence were inaccessible from SEER database.
Otherwise, the lack of records of surgical complications in the SEER database also influenced the complications and overall survival in this study. Additionally, we excluded patients who died within 1 month after surgery to reduce the impact of surgical complications. Chemotherapy treatments are also not available from SEER database. However, we included all patients with early-stage gastric neuroendocrine carcinoma, and chemotherapy that had little effect on overall survival. Anyway, our study enrolls a large population during a long follow-up to reflect real-world clinical outcomes, which is the strength of our study.

In conclusion, in this population-based analysis of T1 G-NEC patients, we demonstrate that tumor > 2 cm is the most significant risk factor of metastasis for T1 G-NEC. ET is likely to be adequate for lesions with mucosa involvement and tumors \( \leq 2 \) cm. Further prospective studies are warranted to evaluate the risk of metastasis and long-term outcomes after different treatment modalities.

### Table 4: Cox regression analysis of OS and CSS in patients with stage T1 gastric neuroendocrine carcinoma

| Characteristic                      | OS                        | CSS                        |
|-------------------------------------|---------------------------|---------------------------|
|                                     | Multivariate analysis     | Multivariate analysis     |
|                                     | HR (95% CI)                | HR (95% CI)                |
|                                     | Reference                  | Reference                  |
| **Age (years)**                     |                           |                           |
| Up to 59                            | Reference                  | Reference                  |
| 60+                                 | 2.851 (1.330–6.112)       | 6.077 (10.260–29.300)     |
| Gender                              |                           |                           |
| Female                              | Reference                  | Reference                  |
| Male                                | 1.688 (0.872–3.269)       | 4.699 (0.896–24.657)      |
| Race                                |                           |                           |
| White                               | Reference                  | Reference                  |
| Black                               | 0.710 (0.277–1.817)       | 1.002 (0.193–5.202)       |
| Others\(^a\)                        | 0.999 (0.222–4.504)       | 1.180 (0.079–17.732)      |
| **Year of diagnosis**               |                           |                           |
| 2004–2009                           | Reference                  | Reference                  |
| 2010–2015                           | 0.432 (0.208–0.897)       | 0.132 (0.027–0.637)       |
| **Tumor size (cm)**                 |                           |                           |
| < 1                                 | Reference                  | Reference                  |
| 1–2                                 | 0.520 (0.198–1.366)       | 0.623 (0.087–4.477)       |
| 2+                                  | 1.052 (0.441–2.511)       | 2.522 (0.480–13.246)      |
| **Invasion depth**                  |                           |                           |
| Mucosal involvement                 | Reference                  | Reference                  |
| Submucosal involvement              | 1.751 (0.700–4.375)       | 0.522 (0.070–3.877)       |
| Mucosal or submucosal, not otherwise specified | 1.988 (0.756–5.225) | 1.163 (0.222–6.093)      |
| **Grade**                           |                           |                           |
| Well-differentiated                 | Reference                  | Reference                  |
| Moderately differentiated           | 2.391 (0.885–6.460)       | 14.028 (1.828–107.652)    |
| Poorly/undifferentiated             | 5.0171.25120.113           | 78.286 (7.659–800.202)    |
| Unknown                             | 3.0731.2477.570           | 9.562 1 (0.510–60.529)    |
| **Treatment**                       |                           |                           |
| Endoscopic therapy                  | Reference                  | Reference                  |
| Surgery                             | 0.844 (0.395–1.805)       | 1.375 (0.289–6.533)       |

\(^a\)American Indian/Alaska Native, Asian/Pacific Islander
Acknowledgements The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER database. The interpretation and reporting of these data are the sole responsibility of the authors. This study was supported by Medical Scientific Research Foundation of Zhejiang Province, China (Grant No. 2019K1Y1010), Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province (2019E10020). Supported by Ningbo Clinical Research Center for Digestive System Tumors (Grant No. 2019A21003). Supported by Hwa Mei Research Foundation of Ningbo No. 2 Hospital, China (Grant No. 2020HMKY55). The Oncology Key Special Subject of Ningbo (2022-B09). Health Young Technical Backbone Talents Foundation of Ningbo. Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents.

Author contributions HY, YY, PC, and QZ participated in the design of this project, interpretation of data, and drafting and critical revision of the article and provided final approval of the version to be submitted. HY and PC completed the data collection and analysis.

Declarations

Disclosures Drs. Hua Ye, Yuan Yuan, Ping Chen, Qi Zheng have no conflicts of interest or financial ties to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made.

References

1. Assarazadeh N, Montgomery E (2021) What is new in the 2019 World Health Organization (WHO) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing. Arch Pathol Lab Med 145:664–677
2. Yao JC, Hassan M, Phan A, Di Meglio P, Fante P, Giordano T, He J, Herbst R, Kalemkerian GP, Kim JJ (2018) Clinicopathological features and outcome of type 3 gastric neuroendocrine tumors. J Clin Oncol 36:5005–5014
3. Ko BM, Lee MS (2015) Long-term outcome of endoscopic and surgical resection for foregut neuroendocrine tumors. J Dig Dis 16:595–600
4. Li QL, Zhang YQ, Chen WF, Xu MD, Zhong YS, Ma LL, Qin WZ, Hu JW, Cai MY, Yao LQ, Zhou PH (2012) Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol 18:5799–5806
5. Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI (2003) Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14:175–193
6. Amin MB, Greene FL, Edgerton BR, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99
7. Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, Kato H, Tsuda H, Kushima R (2013) Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol 37:949–959
8. Hirasawa T, Yamamoto N, Sano T (2021) Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study. Dig Endosc 33:408–417
9. Nagtegaal ID, Ozde RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188
10. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tommasetti P, Salazar R, Ruszniewski P (2012) ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 95:74–87
11. Shah MH, Goldner WS, Halfdanarson TR, Bergslund E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarissetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Ubobo NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G (2018) NCCN guidelines insights: neuroendocrine and adren al tumors, version 2.2018. J Natl Compr Cancer Netw 16:693–702
12. Scherübl H, Cadiot G (2017) Early gastroenteropancreatic neuroendocrine tumors: endoscopic therapy and surveillance. Visc Med 33:332–338
13. Min BH, Hong M, Lee JH, Rhee PL, Sohn TS, Kim S, Kim KM, Kim JJ (2018) Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br J Surg 105:1480–1486
14. Kwon YH, Jeon SW, Kim GH, Kim JI, Chung IK, Jee SR, Kim HK, Seo GS, Baik GH, Choi KD, Moon JS (2013) Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 19:8703–8708
15. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedmann B, Niederle B, Sedlackova E, Toumanakis C, Anlauf M, Cwikla JB, Caplin M, O’Toole D, Perren A (2016) ENETS Consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103:186–194

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.